Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>

21 October 2013: UCL Corporate Partnerships team expands

UCL Corporate Partnerships has recently expanded its team with the addition of Dr Michael Morris, who will be working as Corporate Partnerships Manager for The School of the Built Environment, Engineering Sciences, and Mathematical and Physical Sciences (BEAMS). More...

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>